Statistics for Safety and Immunogenicity of H1/IC31H , an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial
Total visits
| views | |
|---|---|
| Safety and Immunogenicity of H1/IC31H , an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial | 0 |
Total visits per month
| views | |
|---|---|
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
File Visits
| views | |
|---|---|
| Safety and Immunogenicity of H1IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cellsmm3 A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controll.pdf | 2 |